SOAT1 and myeloproliferative neoplasm: In accordance with the putative importance of HSP in the pathogenesis of JAK-STAT -related hematological disorders, a recent study described the potential therapeutic use of PU-H71, a HSP90 inhibitor, in experimental models of MPN, ET and PV [13].